Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1995 Apr;39(4):375–380. doi: 10.1111/j.1365-2125.1995.tb04465.x

Pharmacokinetics and pharmacodynamics of tucaresol, an antisickling agent, in healthy volunteers.

P E Rolan 1, A J Mercer 1, R Wootton 1, J Posner 1
PMCID: PMC1365124  PMID: 7640143

Abstract

1. Tucaresol is an orally administered antisickling agent which increases the oxygen affinity of haemoglobin. 2. The pharmacokinetics, effects on moderate graded exercise and psychometric performance of tucaresol were examined in a double-blind, placebo-controlled, parallel groups study in 12 healthy men. 3. Three doses of tucaresol were given at 48 h intervals intended to modify 15, 25 and 32.5% of a subject's haemoglobin to a high affinity form (%MOD). 4. Mean peak %MOD was 34%. Mean Cmax values in plasma and erythrocytes were 81.4 and 1459 micrograms ml-1, respectively. 5. Heart rate, compared with baseline, increased in the tucaresol group with the greatest changes at the highest %MOD and workload. There were no differences between groups in psychometric test performance. 6. Three volunteers on active drug developed fever, rash and tender cervical lymphadenopathy with onset 7-10 days from the start of dosing, suggesting an immune mechanism. 7. The acute increase in oxygen affinity with tucaresol is physiologically well-tolerated, but the utility of tucaresol in the management of sickle cell disease will depend on the identification of a dosing regimen with a lower incidence of drug allergy.

Full text

PDF
375

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beddell C. R., Goodford P. J., Kneen G., White R. D., Wilkinson S., Wootton R. Substituted benzaldehydes designed to increase the oxygen affinity of human haemoglobin and inhibit the sickling of sickle erythrocytes. Br J Pharmacol. 1984 Jun;82(2):397–407. doi: 10.1111/j.1476-5381.1984.tb10775.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Borg G. Perceived exertion as an indicator of somatic stress. Scand J Rehabil Med. 1970;2(2):92–98. [PubMed] [Google Scholar]
  3. Chadwick D., Shaw M. D., Foy P., Rawlins M. D., Turnbull D. M. Serum anticonvulsant concentrations and the risk of drug induced skin eruptions. J Neurol Neurosurg Psychiatry. 1984 Jun;47(6):642–644. doi: 10.1136/jnnp.47.6.642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Dean J., Schechter A. N. Sickle-cell anemia: molecular and cellular bases of therapeutic approaches (first of three parts). N Engl J Med. 1978 Oct 5;299(14):752–763. doi: 10.1056/NEJM197810052991405. [DOI] [PubMed] [Google Scholar]
  5. Dean J., Schechter A. N. Sickle-cell anemia: molecular and cellular bases of therapeutic approaches (third of three parts). N Engl J Med. 1978 Oct 19;299(16):863–870. doi: 10.1056/NEJM197810192991605. [DOI] [PubMed] [Google Scholar]
  6. Franklin I. M., Rosemeyer M. A., Huehns E. R. Sickle cell disease: the proportion of liganded haemoglobin needed to prevent crises. Br J Haematol. 1983 Aug;54(4):579–587. doi: 10.1111/j.1365-2141.1983.tb02137.x. [DOI] [PubMed] [Google Scholar]
  7. Keidan A. J., Franklin I. M., White R. D., Joy M., Huehns E. R., Stuart J. Effect of BW12C on oxygen affinity of haemoglobin in sickle-cell disease. Lancet. 1986 Apr 12;1(8485):831–834. doi: 10.1016/s0140-6736(86)90941-4. [DOI] [PubMed] [Google Scholar]
  8. Keidan A. J., Sowter M. C., Johnson C. S., Marwah S. S., Stuart J. Pharmacological modification of oxygen affinity improves deformability of deoxygenated sickle erythrocytes: a possible therapeutic approach to sickle cell disease. Clin Sci (Lond) 1989 Apr;76(4):357–362. doi: 10.1042/cs0760357. [DOI] [PubMed] [Google Scholar]
  9. Merrett M., Stammers D. K., White R. D., Wootton R., Kneen G. Characterization of the binding of the anti-sickling compound, BW12C, to haemoglobin. Biochem J. 1986 Oct 15;239(2):387–392. doi: 10.1042/bj2390387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Platt O. S. Is there treatment for sickle cell anemia? N Engl J Med. 1988 Dec 1;319(22):1479–1480. doi: 10.1056/NEJM198812013192210. [DOI] [PubMed] [Google Scholar]
  11. Ramsay J. R., Bleehen N. M., Dennis I., Workman P., Ward R., Falk S. J., Bedford P., Wootton R., Nethersell A. B. Phase I study of BW12C in combination with mitomycin C in patients with advanced gastrointestinal cancer. Int J Radiat Oncol Biol Phys. 1992;22(4):721–725. doi: 10.1016/0360-3016(92)90511-f. [DOI] [PubMed] [Google Scholar]
  12. Rolan P. E., Parker J. E., Gray S. J., Weatherley B. C., Ingram J., Leavens W., Wootton R., Posner J. The pharmacokinetics, tolerability and pharmacodynamics of tucaresol (589C80; 4[2-formyl-3-hydroxyphenoxymethyl] benzoic acid), a potential anti-sickling agent, following oral administration to healthy subjects. Br J Clin Pharmacol. 1993 Apr;35(4):419–425. doi: 10.1111/j.1365-2125.1993.tb04160.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Schaffler K., Hörmann E., Arnold H. A pilot study to evaluate the effect of acute and long-term administration of cyclandelate on the vigilance of subjects submitted to hypoxic conditions. Preliminary report. Arzneimittelforschung. 1981;31(6):1032–1035. [PubMed] [Google Scholar]
  14. Schaffler K., Klausnitzer W. Randomized placebo-controlled double-blind cross-over study on antihypoxidotic effects of piracetam using psychophysiological measures in healthy volunteers. Arzneimittelforschung. 1988 Feb;38(2):288–291. [PubMed] [Google Scholar]
  15. Smith S. A., Russell A. E., West M. J., Chalmers J. Automated non-invasive measurement of cardiac output: comparison of electrical bioimpedance and carbon dioxide rebreathing techniques. Br Heart J. 1988 Mar;59(3):292–298. doi: 10.1136/hrt.59.3.292. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Sunshine H. R., Hofrichter J., Eaton W. A. Requirement for therapeutic inhibition of sickle haemoglobin gelation. Nature. 1978 Sep 21;275(5677):238–240. doi: 10.1038/275238a0. [DOI] [PubMed] [Google Scholar]
  17. Wilson J. T., Höjer B., Rane A. Loading and conventional dose therapy with phenytoin in children: kinetic profile of parent drug and main metabolite in plasma. Clin Pharmacol Ther. 1976 Jul;20(1):48–58. doi: 10.1002/cpt197620148. [DOI] [PubMed] [Google Scholar]
  18. Wilson J. T., Höjer B., Tomson G., Rane A., Sjöqvist F. High incidence of a concentration-dependent skin reaction in children treated with phenytoin. Br Med J. 1978 Jun 17;1(6127):1583–1586. doi: 10.1136/bmj.1.6127.1583. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES